Prospective open-label trial of personalised connectivity-guided transcranial magnetic stimulation therapy for migraine
Abstract
BACKGROUND: Migraine is a leading cause of disability worldwide, affecting hundreds of millions of individuals. Repetitive transcranial magnetic stimulation (rTMS) offers a non-invasive therapeutic option, yet long-term effects remain unclear. We investigated whether rTMS treatment effects could be extended by personalising stimulation targets based on connectivity between the pregenual cingulate cortex (PGC) and dorsolateral prefrontal cortex (DLPFC)-a neural pathway implicated in migraine pathophysiology. FINDINGS: Twenty-one patients completed all treatments and assessments. Clinical data were analysed using repeated-measures one-way ANOVAs (Baseline, Post, Follow-up), with comparisons being and Bonferroni correction (2-tailed). Personalised rTMS had a large effect on headache frequency (estimated difference, 4.42, p = 0.004, 95% CI, 1.30–7.54, Cohen’s d, 0.81) and intensity (estimated difference, 2.54, p < 0.001, 95% CI, 0.97–4.10, Cohen d = 0.92), at Follow-up. After treatment, 11/21 (52.38%) patients were classified as responders. The response rate was maintained at 52.38% at Follow-up. Changes in DLPFC-PGC connectivity were able to classify responders from non-responders (AUC, 0.80, p = 0.020, sensitivity, 72.70%, specificity, 80%). CONCLUSIONS: In this study, personalised rTMS treatment demonstrated a large and long-term effect for migraineurs. These novel findings need to be directly compared with conventional group-average targeting strategies in future controlled…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.